Semax belongs to a quieter corner of peptide research — one that developed largely inside Russia, in Russian-language journals, and under a regulatory system that has approved it as a medicine. What this means for the rest of the world, and what the published literature actually supports, is a more nuanced story than most English-language summaries convey.
What: A synthetic seven-amino-acid peptide derived from a fragment of the stress hormone ACTH, developed in Russia and delivered as a nasal spray.
Research areas: Ischemic stroke recovery · Cognitive and attention effects · Optic nerve disorders · Pediatric attention difficulties · Neuroprotection
Evidence: Substantial Russian clinical and animal literature over four decades; almost no independent Western Phase 3 replication.
Status: Approved as a prescription medicine in Russia. Not approved by the EMA, MHRA, or FDA. Sold in Western markets only as a research chemical.
What is Semax?
Semax is a synthetic heptapeptide — seven amino acids — designed as a stable analog of a short fragment of the naturally occurring hormone adrenocorticotropic hormone (ACTH). Specifically, Semax is based on ACTH fragment 4–7 (Met-Glu-His-Phe), extended at the carboxyl end with a Pro-Gly-Pro tripeptide that confers enzymatic stability and substantially increases half-life in the brain compared to the unstable native fragment (Ashmarin et al., 1997).
The key insight behind Semax was decades old by the time the molecule was designed. Early research on ACTH analogs in the 1970s, much of it conducted in the Netherlands and elsewhere in Europe, had suggested that the ACTH 4–10 fragment retained behavioral and cognitive effects of the parent hormone while lacking its steroidogenic (cortisol-producing) activity (de Wied, 1987). The ACTH 4–7 sequence was an even shorter fragment with reported CNS (central nervous system) activity but very short biological half-life. The addition of Pro-Gly-Pro converted a pharmacologically interesting but unstable fragment into a stable molecule suitable for development as a drug.
Origin and development
Semax was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1980s under the leadership of Academician Nikolay Myasoedov, in collaboration with the Institute of Biomedical Chemistry and various clinical centers across the Soviet Union and, later, the Russian Federation (Myasoedov et al., 1999). The program was part of a broader Soviet-era interest in "regulatory peptides" — short endogenous and synthetic sequences with potential CNS and immune-modulating properties — that produced several related compounds, notably Selank, an analog of the endogenous peptide tuftsin developed at the same institute.
The Semax program resulted in a medicinal product that was registered and eventually included on the Russian List of Vital and Essential Medicines for certain neurological indications. The compound has been in continuous clinical use in Russia since approximately 1994.
Regulatory status
Semax is approved as a prescription medicine in the Russian Federation and in a handful of former Soviet states. The approved forms are intranasal solutions at two principal concentrations (0.1% and 1%), corresponding to different indications and delivery approaches. The approved Russian indications include ischemic stroke (as part of combination therapy), cognitive disorders, optic nerve atrophy, and — in the 0.1% nasal spray formulation — attention deficit and cognitive difficulties in children (Gusev et al., 2005).
Semax is not approved by the European Medicines Agency, the UK MHRA, the US FDA, or any other major Western regulator. It has no authorized therapeutic indication anywhere outside of the post-Soviet jurisdictions where its clinical development took place. This regulatory asymmetry — approved in one major jurisdiction, unknown or unauthorized in others — is unusual among modern neuropsychiatric agents.
A substantial portion of the primary research on Semax was published in Russian-language journals such as Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova and Byulleten' Eksperimental'noi Biologii i Meditsiny. Western peer-reviewed coverage is more limited, though it has grown over the past two decades as Russian researchers have increasingly published in English-language journals. Readers should be aware that both literatures exist and that English-language reviews inevitably sample only part of the full body of work.
Proposed mechanisms
BDNF and NGF expression
The most widely cited mechanistic work on Semax concerns its reported effects on neurotrophic factor (proteins that support neuron growth and survival) expression in the brain. Dolotov and colleagues reported in Journal of Neurochemistry that intranasal Semax administration in rats produced increased expression of brain-derived neurotrophic factor (BDNF) and its tyrosine kinase receptor TrkB in the hippocampus and basal forebrain (Dolotov et al., 2006). Subsequent work from Shadrina and colleagues extended these findings using gene expression microarray analysis, reporting modulation of expression of genes involved in neurotrophin signaling, dopaminergic neurotransmission, and immune response (Shadrina et al., 2010).
These findings are often summarized as "Semax increases BDNF." The literature supports this as a description of rodent brain tissue expression data but not as a characterization of clinical mechanism in humans.
Melanocortin receptor activity
As a fragment of ACTH, Semax retains modest activity at melanocortin receptors — the family of G-protein-coupled receptors that mediate many of ACTH's endocrine and central effects. The behavioral pharmacology literature has proposed that some of Semax's cognitive effects may involve MC4R signaling in brain regions associated with learning and attention, though this has not been fully characterized (Potaman et al., 1991). Importantly, Semax does not appear to activate the adrenal cortex in the way full-length ACTH does — the 4–7 fragment lacks the structural motif required for potent steroidogenic activity.
HPA axis modulation
Russian researchers have characterized Semax's effects on the hypothalamic-pituitary-adrenal axis in animal models under stress, with reports of normalizing rather than stimulating stress responses — a profile distinct from classical ACTH (Kamensky et al., 2007).
Dopaminergic effects
Eremin and colleagues published work characterizing Semax's influence on dopaminergic neurotransmission in rat brain, with reports of altered tyrosine hydroxylase expression and changes in dopamine turnover in select brain regions (Eremin et al., 2005). These findings are consistent with the compound's proposed effects on attention and arousal in behavioral tests.
Key research areas
Cognitive and attention research
A significant portion of the Russian research has examined Semax in models of cognitive performance, attention, and learning. Published animal studies have described improved performance on passive avoidance, water maze, and operant conditioning tasks, with the authors proposing BDNF-mediated effects on hippocampal plasticity as a mechanism (Levitskaya et al., 2004).
Human research — nearly all of it in Russian clinical contexts — has examined effects on attention, memory, and cognitive performance in patients with cerebrovascular disease and in healthy volunteers under cognitive load. Results published in Russian neurology journals have reported improvements on various cognitive assessment batteries, though the methodological rigor of these studies varies, and few have been replicated by independent Western groups.
Ischemic stroke research
The most substantial clinical literature on Semax concerns its use as an adjunctive therapy in acute ischemic stroke. Gusev and colleagues published a series of clinical studies in Russian patients with ischemic stroke, reporting faster neurological recovery and improved functional outcomes when Semax was added to standard care in the acute phase (Gusev et al., 2005). These reports formed part of the regulatory basis for Semax's approval in that indication in Russia.
Preclinical stroke research has included studies in rodent middle cerebral artery occlusion models (a standard surgical way of simulating a stroke in rats), where Semax administration was reported to reduce infarct volume and improve behavioral recovery (Romanova et al., 2006).
Optic nerve and visual system research
Russian clinical research has examined Semax in optic neuropathy and other visual system disorders, with published reports of improvements in visual acuity and visual field parameters in patients with ischemic optic neuropathy (Polunin et al., 2000). This is one of the officially approved Russian indications.
Pediatric ADHD and cognitive disorders
The 0.1% Semax nasal spray formulation has been studied in pediatric populations with attention-deficit and cognitive difficulties. Published Russian research has reported improvements on behavioral and cognitive measures, though the trials have generally been small, open-label, and conducted at Russian clinical centers without independent Western replication (Maslova et al., 2001).
Neuroprotection
Beyond stroke, Semax has been examined in broader neuroprotection research, including models of traumatic brain injury, hypoxia, and neurodegenerative processes. Published studies have reported effects consistent with reduced oxidative damage and preserved neuronal function in rodent injury models (Bashkatova et al., 2001).
Clinical use in Russia
In current Russian clinical practice, Semax is used for several indications including acute and subacute ischemic stroke (in hospital settings), chronic cerebrovascular insufficiency, cognitive disorders of vascular origin, optic nerve disorders of ischemic origin, and in pediatric practice for attention and cognitive difficulties in children. It is typically administered intranasally, with published treatment courses spanning days to several weeks depending on indication.
Whether this pattern of clinical use would survive the more rigorous evidence standards applied by EMA or FDA is unknown — the pivotal Western-style trials have not been conducted, and the historical Russian trials, while numerous, generally do not meet modern international standards for randomization, blinding, and outcome assessment.
Current state of evidence
- Substantial Russian clinical and preclinical literature. A genuine body of research exists, spanning four decades, published primarily in Russian-language journals with a growing English-language presence.
- Approved medical use in Russia. Unusually for compounds in this class, Semax is a regulated prescription medicine in at least one major jurisdiction, with defined indications and pharmaceutical-grade manufacturing.
- Limited Western peer-reviewed replication. Independent Western research teams have not systematically replicated the Russian clinical findings, and pivotal Western-style Phase 3 trials are absent.
- Mechanistic plausibility. The BDNF, neurotrophin, and melanocortin mechanisms are broadly plausible and supported by in vitro and animal data.
- Nootropic and cognitive enhancement claims in healthy users are not well-supported by high-quality randomized controlled trial evidence.
What the research does not show
- No Western regulatory approval — Semax is not authorized for any indication by EMA, MHRA, or FDA.
- No large, independent, Western-style Phase 3 trials for any indication.
- No demonstrated long-term safety profile in peer-reviewed Western literature, beyond the clinical experience accumulated in Russia.
- No evidence for cognitive enhancement in healthy populations at the level of rigor required for pharmaceutical indications.
- No peer-reviewed pharmacokinetic data from Western clinical trial infrastructure, though Russian pharmacokinetic studies exist.
Nasal delivery format
A distinctive feature of Semax is its intranasal route of administration. The nasal epithelium (the tissue lining the inside of the nose) provides direct access to the olfactory and trigeminal pathways, which in turn project to brain regions without requiring crossing of the blood-brain barrier. Published pharmacokinetic research has reported that intranasal Semax reaches measurable concentrations in rat brain tissue within minutes of administration, with the authors proposing direct olfactory-to-brain transport as a major delivery route (Shevchenko et al., 2006). The approved Russian pharmaceutical product is formulated as a nasal drop rather than an injectable.
Related compound: Selank
Semax is often discussed alongside Selank, a heptapeptide analog of the endogenous immunomodulator tuftsin, developed at the same Russian institute and approved for similar indications in Russia as an anxiolytic rather than a cognitive agent. Selank represents an adjacent research program from the same scientific lineage and is sometimes studied in parallel, though the two compounds have distinct proposed mechanisms (Zozulya et al., 2008).
This article is a summary of published research. Semax has a genuine Russian clinical development history and is an approved medicine in that jurisdiction, but it is not approved as a medicine in the EU, UK, or US. At no point should this article be read as instruction for human use. It is sold in Western markets strictly as a research chemical for laboratory and in-vitro research.